Lyra Therapeutics, Inc.

Lyra Therapeutics (LYRA) has logged zero cyber incidents and zero red-flag 8-K filings in our 90-day detection window, suggesting operational stability over the near term. However, low signal in a short window does not indicate low fundamental risk; the company's capital structure, dilution trajectory, and financing history require deeper analysis. The full $49 Report extends the lookback to 12 months, calculates dilution risk scores, maps 8-K context, and flags AI-related risk signals that shape medium-term shareholder value. The full $49 Report adds quantified dilution exposure, comprehensive financing timeline, and forward-risk scoring across capital and operational dimensions.